1. Isolation and characterization of severe acute respiratory syndrome coronavirus 2 in Turkey
- Author
-
Gunsu Aydin, Hazel Yetiskin, Ceren Cevik, Can Holyavkin, Aykut Ozdarendeli, Muhammet Ali Uygut, Shaikh Terkis Islam Pavel, Zehra Beştepe Dursun, and İlhami Çelik
- Subjects
RNA viruses ,Viral Diseases ,Turkey ,Coronaviruses ,viruses ,Artificial Gene Amplification and Extension ,Iran ,Virus Replication ,Polymerase Chain Reaction ,Nucleocapsids ,Medical Conditions ,Cytopathogenic Effect, Viral ,Nasopharynx ,Chlorocebus aethiops ,Medicine and Health Sciences ,Medicine ,Phylogeny ,Pathology and laboratory medicine ,Data Management ,Travel ,Multidisciplinary ,Phylogenetic Analysis ,Genomics ,Medical microbiology ,Phylogenetics ,Infectious Diseases ,England ,Kuwait ,Viruses ,SARS CoV 2 ,Pathogens ,Coronavirus Infections ,Research Article ,Canada ,2019-20 coronavirus outbreak ,Computer and Information Sciences ,DNA, Complementary ,Virus Cultivation ,Coronavirus disease 2019 (COVID-19) ,Isolation (health care) ,SARS coronavirus ,Science ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Pneumonia, Viral ,Genome, Viral ,Viral Structure ,Research and Analysis Methods ,Microbiology ,Cell Line ,Betacoronavirus ,Viral genetics ,Virology ,Genetics ,Animals ,Humans ,Evolutionary Systematics ,Molecular Biology Techniques ,Pandemics ,Vero Cells ,Molecular Biology ,Taxonomy ,SARS ,Evolutionary Biology ,Biology and life sciences ,SARS-CoV-2 ,business.industry ,Australia ,Organisms ,Viral pathogens ,COVID-19 ,Covid 19 ,Sequence Analysis, DNA ,medicine.disease ,Macaca mulatta ,Viral Replication ,Microbial pathogens ,Pneumonia ,DNA, Viral ,Contact Tracing ,business ,HeLa Cells - Abstract
Copyright: © 2020 Pavel et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and associated with severe respiratory illness emerged in Wuhan, China, in late 2019. The virus has been able to spread promptly across all continents in the world. The current pandemic has posed a great threat to public health concern and safety. Currently, there are no specific treatments or licensed vaccines available for COVID-19. We isolated SARS-CoV-2 from the nasopharyngeal sample of a patient in Turkey with confirmed COVID-19. We determined that the Vero E6 and MA-104 cell lines are suitable for supporting SARS-CoV-2 that supports viral replication, development of cytopathic effect (CPE) and subsequent cell death. Phylogenetic analyses of the whole genome sequences showed that the hCoV-19/Turkey/ERAGEM-001/2020 strain clustered with the strains primarily from Australia, Canada, England, Iran and Kuwait and that the cases in the nearby clusters were reported to have travel history to Iran and to share the common unique nucleotide substitutions.
- Published
- 2020